Funding for this research was provided by:
Cancerfonden (2016-486, 2016-438, 20 0306 PjF)
Vetenskapsrådet (2017-01392, 2016-01530)
Stiftelsen Assar Gabrielssons Fond
The Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement (71632, 721091)
BioCARE National Strategic Research Program at the University of Gothenburg
Received: 2 October 2020
Accepted: 28 January 2021
First Online: 22 February 2021
Ethics approval and consent to participate
: The original study (SBII:2) was approved by the Ethics Committee at Lund and Linköping Universities, Sweden (D.nr LU 240–01 and for the continuation of the study: D.nr Linköping 01–134 and D.nr LU 2015–350). Randomization was performed by the Regional Oncological Centers where verbal informed consent was registered for all patients, approved by the Ethics Committee.
: Not applicable.
: None reported.